The early history of King Edward VIII Hospital, Durban

No Abstrac

Further studies utilizing hormones to alter estrous cycles and fertility

In one large dairy herd, we examined the reproductive performance of 943 cows following early postpartum hormonal therapy utilizing gonadotropin-releasing hormone (GnRH or Cystorelin®) and prostaglandin F2-alpha (PGF). None of our hormonal treatments improved reproductive efficiency in this herd, whereas earlier studies at the KSU Dairy Teaching and Research Center had proved beneficial. However, cows given PGF to induce estrus at the beginning of the breeding period had similar reproductive performance to control cows, suggesting a potential use for one injection of PGF to allow the breeding of more cows by a target date after calving (e.g., by 65 days)

The impact of phosphorus fertilizer placement on crop production

Non-Peer ReviewedImproved phosphorus (P) fertilizer management is viewed as a way to improve yields in highly productive cropping system. A study was conducted at numerous sites during the 1990’s to assess plant density and yield of canola (Brassica napus L.), barley (Hordeum vulgare L.), spring wheat (Triticum aestivum L.), and winter wheat respond to greater P fertilizer rates (0, 15, 30, 45, and 60 kg P ha-1) when seed placed and side banded. We did find that canola stand was insensitive to rates of P tested when banded, but greater rates of seed-placed P caused stand thinning. It is thought the compensatory growth of canola was the reason why canola yield did not respond to P treatment. Both barley and winter wheat yielded most when the greatest rates of P were applied. Spring wheat showed a similar response when P was side banded, thus indicating improved tolerance with P placed away from seed. Therefore, spring wheat was the only crop that fit with our hypotheses; side banding P will allow crops to respond positively to greater rates of P fertilizer. The fact the cereal crop density was unresponsive to P management indicates that seedlings show early-season better tolerance than canola. Unlike canola, yield-forming factors for cereal crops responded to greater rates of P

Influence of prebreeding progesterone plus prostaglandin F2-α on estrus and fertility in lactating dairy cows

Progesterone administered before breeding may increase estrous expression and subsequent fertility in lactating dairy cows. Holstein cows (n=302) were assigned randomly at calving to three groups. Cows received no treatment (controls), one injection of prostaglandin F 2-α (PGF), or progesterone plus one injection of PGF (PRID + PGF). The average interval to estrus was 5 days shorter in PRID + PGF cows compared to cows given only PGF. In addition, more cows were observed in estrus 2 to 5 days after treatment in the PRID + PGF group compared to the PGF group. Average days from calving to conception were reduced in PRID + PGF cows by 15 to 20 days compared to control and PGF cows. We concluded that prebeeding progesterone in combination with PGF appears to enhance fertility.; Dairy Day, 1987, Kansas State University, Manhattan, KS, 1987

Together, yet still not equal? Sex integration in equestrian sport

Sex segregation is a core organising principle of most modern sports and is a key element in the marginalisation and subordination of girls and women in sport and beyond. In this article I explore the only Olympic-level sport which is not organised around sex segregation – equestrian sport – in order to consider the implications of sex integration for female participants. I draw on a study conducted on elite riders that found that although sex integration in equestrian sport does not lead to female participants being excluded from high-level competition, men continue to perform disproportionately well. This suggests that although sex integration may be an important step towards breaking down gender hierarchies in sport, without accompanying wider changes in gender norms and expectations, sex integration alone will not be enough to achieve greater gender equality in equestrian sport

Non-perturbative calculations for the effective potential of the PTPT symmetric and non-Hermitian (−gϕ4)(-g\phi^{4}) field theoretic model

We investigate the effective potential of the $PT$ symmetric $(-g\phi^{4})$ field theory, perturbatively as well as non-perturbatively. For the perturbative calculations, we first use normal ordering to obtain the first order effective potential from which the predicted vacuum condensate vanishes exponentially as $G\to G^+$ in agreement with previous calculations. For the higher orders, we employed the invariance of the bare parameters under the change of the mass scale $t$ to fix the transformed form totally equivalent to the original theory. The form so obtained up to $G^3$ is new and shows that all the 1PI amplitudes are perurbative for both $G\ll 1$ and $G\gg 1$ regions. For the intermediate region, we modified the fractal self-similar resummation method to have a unique resummation formula for all $G$ values. This unique formula is necessary because the effective potential is the generating functional for all the 1PI amplitudes which can be obtained via $\partial^n E/\partial b^n$ and thus we can obtain an analytic calculation for the 1PI amplitudes. Again, the resummed from of the effective potential is new and interpolates the effective potential between the perturbative regions. Moreover, the resummed effective potential agrees in spirit of previous calculation concerning bound states.Comment: 20 page

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial

Background: Peri-operative chemotherapy and surgery is a standard of care for patients with resectable oesophagogastric adenocarcinoma. Bevacizumab, a monoclonal antibody against VEGF, improves the proportion of patients responding to treatment in advanced gastric cancer. We aimed to assess the safety and efficacy of adding bevacizumab to peri-operative chemotherapy in patients with resectable gastric, oesophagogastric junction, or lower oesophageal adenocarcinoma. Methods: In this multicentre, randomised, open-label phase 2–3 trial, we recruited patients aged 18 years and older with histologically proven, resectable oesophagogastric adenocarcinoma from 87 UK hospitals and cancer centres. We randomly assigned patients 1:1 to receive peri-operative epirubicin, cisplatin, and capecitabine chemotherapy or chemotherapy plus bevacizumab, in addition to surgery. Patients in the control group (chemotherapy alone) received three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1–21. Patients in the investigational group received the same treatment as the control group plus 7·5 mg/kg intravenous bevacizumab on day 1 of every cycle of chemotherapy and for six further doses once every 21 days following chemotherapy, as maintenance treatment. Randomisation was done by means of a telephone call to the Medical Research Council Clinical Trials Unit, where staff used a computer programme that implemented a minimisation algorithm with a random element to establish the allocation for the patient at the point of randomisation. Patients were stratified by chemotherapy centre, site of tumour, and tumour stage. The primary outcome for the phase 3 stage of the trial was overall survival (defined as the time from randomisation until death from any cause), analysed in the intention-to-treat population. Here, we report the primary analysis results of the trial; all patients have completed treatment and the required number of primary outcome events has been reached. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN 46020948, and with ClinicalTrials.gov, number NCT00450203. Findings: Between Oct 31, 2007, and March 25, 2014, 1063 patients were enrolled and randomly assigned to receive chemotherapy alone (n=533) or chemotherapy plus bevacizumab (n=530). At the time of analysis, 508 deaths were recorded (248 in the chemotherapy alone group and 260 in the chemotherapy plus bevacizumab group). 3-year overall survival was 50·3% (95% CI 45·5–54·9) in the chemotherapy alone group and 48·1% (43·2–52·7) in the chemotherapy plus bevacizumab group (hazard ratio [HR] 1·08, 95% CI 0·91–1·29; p=0·36). Apart from neutropenia no other toxic effects were reported at grade 3 or worse severity in more than 10% of patients in either group. Wound healing complications were more prevalent in the bevacizumab group, occurring in 53 (12%) patients in this group compared with 33 (7%) patients in the chemotherapy alone group. In patients who underwent oesophagogastrectomy, post-operative anastomotic leak rates were higher in the chemotherapy plus bevacizumab group (23 [10%] of 233 in the chemotherapy alone group vs 52 [24%] of 220 in the chemotherapy plus bevacizumab group); therefore, recruitment of patients with lower oesophageal or junctional tumours planned for an oesophagogastric resection was stopped towards the end of the trial. Serious adverse events for all patients included anastomotic leaks (30 events in chemotherapy alone group vs 69 in the chemotherapy plus bevacizumab group), and infections with normal neutrophil count (42 events vs 53). Interpretation: The results of this trial do not provide any evidence for the use of bevacizumab in combination with peri-operative epiribicin, cisplatin, and capecitabine chemotherapy for patients with resectable gastric, oesophagogastric junction, or lower oesophageal adenocarcinoma. Bevacizumab might also be associated with impaired wound healing. Funding: Cancer Research UK, MRC Clinical Trials Unit at University College London, and F Hoffmann-La Roche Limited

Two-Loop O(αsGFmt2){\cal O}(\alpha_sG_Fm_t^2) Corrections to the Fermionic Decay Rates of the Standard-Model Higgs Boson

Low- and intermediate mass Higgs bosons decay preferably into fermion pairs. The one-loop electroweak corrections to the respective decay rates are dominated by a flavour-independent term of ${\cal O}(G_Fm_t^2)$. We calculate the two-loop gluon correction to this term. It turns out that this correction screens the leading high-$m_t$ behaviour of the one-loop result by roughly 10\%. We also present the two-loop QCD correction to the contribution induced by a pair of fourth-generation quarks with arbitrary masses. As expected, the inclusion of the QCD correction considerably reduces the renormalization-scheme dependence of the prediction.Comment: 14 pages, latex, figures 2-5 appended, DESY 94-08

A Phenomenological Analysis of Gluon Mass Effects in Inclusive Radiative Decays of the J/ψ\rm{J/\psi} and $\Upsilon

The shapes of the inclusive photon spectra in the processes \Jp \to \gamma X and \Up \to \gamma X have been analysed using all available experimental data. Relativistic, higher order QCD and gluon mass corrections were taken into account in the fitted functions. Only on including the gluon mass corrections, were consistent and acceptable fits obtained. Values of $0.721^{+0.016}_{-0.068}$ GeV and $1.18^{+0.09}_{-0.29}$ GeV were found for the effective gluon masses (corresponding to Born level diagrams) for the \Jp and \Up respectively. The width ratios \Gamma(V \to {\rm hadrons})/\Gamma(V \to \gamma+ {\rm hadrons}) V=\Jp, \Up were used to determine $\alpha_s(1.5 {\rm GeV})$ and $\alpha_s(4.9 {\rm GeV})$. Values consistent with the current world average $\alpha_s$ were obtained only when gluon mass correction factors, calculated using the fitted values of the effective gluon mass, were applied. A gluon mass $\simeq 1$ GeV, as suggested with these results, is consistent with previous analytical theoretical calculations and independent phenomenological estimates, as well as with a recent, more accurate, lattice calculation of the gluon propagator in the infra-red region.Comment: 50 pages, 11 figures, 15 table